Remimazolam tosylate - Jiangsu Hengrui Medicine
Alternative Names: HR-7056; Remimazolam tosilateLatest Information Update: 01 Jul 2025
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Benzodiazepines; General anaesthetics; Halogenated hydrocarbons; Hypnosedatives; Imidazoles; Local anaesthetics; Propionates; Pyridines; Sleep disorder therapies; Small molecules
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Anaesthesia; Sedation
- Discontinued Insomnia
Most Recent Events
- 25 Jun 2025 Jiangsu HengRui Medicine plans a phase II trial for Sedation (In children, In adolescents) in China, in July 2025 (Parenteral, Injection) (NCT07036419)
- 24 Jan 2025 Launched for Anaesthesia in China (IV) (Jiangsu Hengrui Medicine pipeline, January 2025)
- 09 Jan 2025 Chemical structure information added.